TITLE

Prevalence of Delayed Clinician Response to Elevated Prostate-Specific Antigen Values

AUTHOR(S)
Nepple, Kenneth G.; Joudi, Fadi N.; Hillis, Stephen L.; Wahls, Terry L.
PUB. DATE
April 2008
SOURCE
Mayo Clinic Proceedings;Apr2008, Vol. 83 Issue 4, p439
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To assess the frequency of delayed response to an abnormal prostate-specific antigen (PSA) value. PATIENTS AND METHODS: Retrospective review of prostate cancer cases diagnosed between January 1, 2000, and December 31, 2005, in a rural Department of Veterans Affairs health care system serving 44,000 veterans across 2 states. Clinician response was defined as a reference to the elevated PSA result in clinical notes, orders for further evaluation, treatment of presumed prostatitis, or a urology visit or referral. Delay was measured as days between an abnormal PSA result and clinician response. RESULTS: We Identified 327 men who met inclusion criteria with an abnormal PSA value before prostate cancer diagnosis. At first PSA elevation, median age was 64 years; 94% were younger than 75 years. Of the 327 men, 253 (77.4%) had a timely (≤30 days) response to an abnormal PSA value; 23 (7.0%) had between 31 and 180 days; 24 (7.3%), between 181 and 360 days; and 27 (8.3%), more than 360 days between an abnormal PSA measurement and clinician response. The delayed group had nearly an additional year's (309 days) lapse before completed urologic consultation and prostate gland biopsy (313 days) as compared with the timely group. The presence of urologic symptoms, abnormal results from rectal examination, higher PSA values, and higher PSA velocity (P<.05) were associated with timely clinician response to an abnormal PSA measurement. CONCLUSION: in a cohort of men with prostate cancer and an antecedent abnormal PSA value, 15.6% had more than 180 days between an abnormal PSA measurement and clinician response. These findings add to the growing literature demonstrating that missed results occur more frequently than is generally appreciated. Improved systems for clinical data management are needed.
ACCESSION #
31718750

 

Related Articles

  • High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. Ghods, Roya; Ghahremani, Mohammad-Hossein; Madjd, Zahra; Asgari, Mojgan; Abolhasani, Maryam; Tavasoli, Sanaz; Mahmoudi, Ahmad-Reza; Darzi, Maryam; Pasalar, Parvin; Jeddi-Tehrani, Mahmood; Zarnani, Amir-Hassan // Cancer Immunology, Immunotherapy;Dec2014, Vol. 63 Issue 12, p1319 

    Background: The scarcity of effective therapeutic approaches for prostate cancer (PCa) has encouraged steadily growing interest for the identification of novel antigenic targets. Placenta-specific 1 (PLAC1) is a novel cancer-testis antigen with reported ectopic expression in a variety of tumors...

  • Treatment of localized prostate cancer. Burchardt, Martin; Huland, Hartwig // World Journal of Urology;Feb2007, Vol. 25 Issue 1, p1 

    The authors reflect on the treatment of localized prostate cancer. They express that with prevalent use of prostate-specific antigen (PSA) for detection of prostate cancer, better chance of cure has been given and possibility of overtreatment has evolved. They point out that PSA has lacked of...

  • A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Hanninen, Mikael; Venner, Peter; North, Scott // Canadian Urological Association Journal;Oct2009, Vol. 3 Issue 5, p369 

    Introduction: Docetaxel chemotherapy prolongs survival in metastatic hormone-refractory prostate cancer (mHRPC), but many patients fail to respond to this therapy and there is potential for serious toxicity. Patients differ in their percent prostate-specific antigen (PSA) decline and rate of PSA...

  • Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Thompson, Ian M.; Ankerst, Donna Pauler; Chen Chi; Goodman, Phyllis J.; Tangen, Catherine M.; Lucia, M. Scott; Ziding Feng; Parnes, Howard L.; Coltman Jr., Charles A. // JNCI: Journal of the National Cancer Institute;4/19/2006, Vol. 98 Issue 8, p529 

    Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who...

  • Three factors predict death from recurring prostate Ca. Hilton, Lisette // Urology Times;10/1/2005, Vol. 33 Issue 12, p1 

    Reports that researchers at the Brady Urological Institute at Johns Hopkins have identified three risk factors that help determine whether a patient's risk of death from recurrent prostate cancer is high or low following surgery. Prostate-specific antigen doubling time; Time from surgery to...

  • Enzyme inhibitor effective against refractory PCa. Kuznar, Wayne // Urology Times;10/1/2009, Vol. 37 Issue 11, p24 

    The article discusses a study performed by researchers from Royal Mardsen Hospital in London, England which found that a specific and irreversible inhibitor of the enzyme CYP17 is effective in treating men with castration-resistant prostate cancer. The study showed that the CYP17 can reduce the...

  • Prostate cancer management shows major shifts in PSA era. Dosa, Laszlo // Urology Times;5/1/2005, Vol. 33 Issue 5, p9 

    This article discusses the trends in prostate cancer management discussed by experts at a session of the 2005 Multidisciplinary Prostate Cancer Symposium held in Orlando, Florida. The management of localized prostate cancer has undergone a significant, dramatic shift in recent years. Both pure...

  • Survival with IAD, CAD similar after PSA relapse. Kent, Heather // Urology Times;5/1/2006, Vol. 34 Issue 5, p23 

    The article discusses the similar effects of progression-free survival and androgen therapies following the deterioration of prostate specific antigen (PSA). It was shown in a study that PSA doubling time was greater in men who were off-treatment for a longer time compared to treatment given in...

  • Adjuvant RT shows benefit in pT3 PCa. Dosa, Laszlo // Urology Times;7/1/2005, Vol. 33 Issue 8, p9 

    Reports on a study which found that adjuvant radiotherapy for prostate cancer significantly reduces the risk of biochemical progression after radical prostatectomy with a very low rate of side effects, according to German researchers. Indication that radiotherapy is better than wait-and-see for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics